Advertisement

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Deborah Collyar: What's In It for Patients?

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Advertisement

Advertisement

Jul

01

Today In Oncology

Pooled Analysis of 5-Year Outcomes With Ultra-Hypofractionated SABR in Primary Renal Cell Carcinoma

FDA Approves Capivasertib Plus Abiraterone and Prednisone for Metastatic Prostate Cancer

ASCO Remembers Karnofsky Award Recipient Maura Gillison Pioneer in HPV-Associated Cancers

Novel Risk Score Stratifies Major Bleeding Risks in Patients With VTE on DOACs

Long-Term Outcomes With SABR in Primary Kidney Cancer

Advertisement

© 2026 HSP News Service, L.L.C.